Key result
Lamotrigine inhibited 60% of INa peak amplitude and 67% of INaL in cardiomyocytes from epileptic rats, reducing cardiac excitability and prolonging the action potential refractory period.
Why the study?
Following an FDA warning on conduction anomalies and Brugada syndrome patterns in patients treated with lamotrigine, the study investigated whether lamotrigine blocks the cardiac sodium current INa.
Does lamotrigine block cardiac sodium current (INa) in cardiomyocytes from epileptic rats?
Does lamotrigine block cardiac sodium current (INa) in cardiomyocytes from epileptic rats?
Lamotrigine significantly blocks cardiac sodium currents and prolongs the action potential refractory period in epileptic rats, providing a potential mechanism for acquired arrhythmias and Brugada-like ECG patterns observed clinically.
May warrant ECG caution with lamotrigine; leaves open causal link to conduction anomalies or Brugada patterns.
Lamotrigine is widely prescribed to treat bipolar neurological disorder and epilepsy. It exerts its antiepileptic action by blocking voltage-gated sodium channels in neurons. Recently, the US Food and Drug Administration issued a warning on the use of Lamotrigine after observations of conduction anomalies and Brugada syndrome patterns on the electrocardiograms of epileptic patients treated with the drug. Brugada syndrome and conduction disturbance are both associated with alterations of the cardiac sodium current (INa) kinetics and amplitude. In this study, we used the patch clamp technique on cardiomyocytes from epileptic rats to test the hypothesis that Lamotrigine also blocks INa in the heart. We found that Lamotrigine inhibited 60% of INa peak amplitude and reduced cardiac excitability in epileptic rats but had little effect in sham animals. Moreover, Lamotrigine inhibited 67% of INaL and, more importantly, prolonged the action potential refractory period in epileptic animals. Our results suggest that enhanced affinity of Lamotrigine for INa may in part explain the clinical phenotypes observed in epileptic patients.
No takes yet. Share an insight, caveat, or question.
Vite et al. (2022) studied Epilepsy. Lamotrigine vs. Sham animals was evaluated on Cardiac sodium current (INa) peak amplitude and INaL. Lamotrigine inhibited 60% of INa peak amplitude and 67% of INaL in cardiomyocytes from epileptic rats, reducing cardiac excitability and prolonging the action potential refractory period.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: